Catherine Gebhard

Catherine Gebhard

Auto-generated profile, based on publicly available information

Catherine Gebhard

Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2020 in Biology of Sex Differences
Verified
Journal Article
Open access
PDF file
CGCatherine Gebhard
Catherine Gebhard
VRVera Regitz-Zagrosek
Vera Regitz-Zagrosek
HNHannelore K. Neuhauser
Hannelore K. Neuhauser
RMRosemary Morgan
Rosemary Morgan
SKSabra L. Klein
Sabra L. Klein
Background: Emerging evidence from China suggests that coronavirus disease 2019 (COVID-19) is deadlier for infected men than women with a 2.8% fatality rate being reported in Chinese men versus 1.7% in women. Further, sex-disaggregated data for COVID-19 in several European countries show a similar number of cases between the sexes, but more severe outcomes in aged men. Case fatality is highest in men with pre-existing cardiovascular conditions. The mechanisms accounting for the reduced case fatality rate in women are currently unclear but may offer potential to develop novel risk stratification tools and therapeutic options for women and men.Content: The present review summarizes latest clinical and epidemiological evidence for gender and sex differences in COVID-19 from Europe and China. We discuss potential sex-specific mechanisms modulating the course of disease, such as hormone-regulated expression of genes encoding for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) entry receptors angiotensin converting enzyme (ACE) 2 receptor and TMPRSS2 as well as sex hormone-driven innate and adaptive immune responses and immunoaging. Finally, we elucidate the impact of gender-specific lifestyle, health behavior, psychological stress, and socioeconomic conditions on COVID-19 and discuss sex specific aspects of antiviral therapies.Conclusion: The sex and gender disparities observed in COVID-19 vulnerability emphasize the need to better understand the impact of sex and gender on incidence and case fatality of the disease and to tailor treatment according to sex and gender. The ongoing and planned prophylactic and therapeutic treatment studies must include prospective sex- and gender-sensitive analyses.

26 December 2019 in European Heart Journal
Verified
Journal Article
Closed access
AHAchi Haider
Achi Haider
SBSusan Bengs
Susan Bengs
JLJudy Luu
Judy Luu
EOElena Osto
Elena Osto
JSJolanta M. Siller-Matula
Jolanta M. Siller-Matula
CGCatherine Gebhard
Catherine Gebhard
Although health disparities in women presenting with acute coronary syndrome (ACS) have received growing attention in recent years, clinical outcomes from ACS are still worse for women than for men. Women continue to experience higher patient and system delays and receive less aggressive invasive treatment and pharmacotherapies. Gender- and sex-specific variables that contribute to ACS vulnerability remain largely unknown. Notwithstanding the sex differences in baseline coronary anatomy and function, women and men are treated the same based on guidelines that were established from experimental and clinical trial data over-representing the male population. Importantly, younger women have a particularly unfavourable prognosis and a plethora of unanswered questions remains in this younger population. The present review summarizes contemporary evidence for gender and sex differences in vascular biology, clinical presentation, and outcomes of ACS. We further discuss potential mechanisms and non-traditional risk conditions modulating the course of disease in women and men, such as unrecognized psychosocial factors, sex-specific vascular and neural stress responses, and the potential impact of epigenetic modifications.

29 June 2012 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
MFMichael Fiechter
Michael Fiechter
JGJelena R. Ghadri
Jelena R. Ghadri
CGCathérine Gebhard
Cathérine Gebhard
TFTobias A. Fuchs
Tobias A. Fuchs
APAju P. Pazhenkottil
Aju P. Pazhenkottil
PKPhilipp A. Kaufmann
Philipp A. Kaufmann
The ability to obtain quantitative values of flow and myocardial flow reserve (MFR) has been perceived as an important advantage of PET over conventional nuclear myocardial perfusion imaging (MPI). We evaluated the added diagnostic value of MFR over MPI alone as assessed with (13)N-ammonia and PET/CT to predict angiographic coronary artery disease (CAD). Seventy-three patients underwent 1-d adenosine stress-rest (13)N-ammonia PET/CT MPI, and MFR was calculated. The added value of MFR as an adjunct to MPI for predicting CAD (luminal narrowing ≥ 50%) was evaluated using invasive coronary angiography as a standard of reference. Per patient, the sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of MPI for detecting significant CAD were 79%, 80%, 91%, 59%, and 79%, respectively. Adding a cutoff of less than 2.0 for global MFR to MPI findings improved the values to 96% (P < 0.005), 80%, 93%, 89% (P < 0.005), and 92% (P < 0.005), respectively. The quantification of MFR in (13)N-ammonia PET/CT MPI provides a substantial added diagnostic value for detection of CAD. Particularly in patients with normal MPI results, quantification of MFR helps to unmask clinically significant CAD.

1 September 2020 in Journal of Cardiovascular Computed Tomography
Verified
Journal Article
Closed access
DBDominik C. Benz
Dominik C. Benz
GBGeorgios Benetos
Georgios Benetos
Georgios RampidisGeorgios Rampidis
Georgios Rampidis
EFElia von Felten
Elia von Felten
ABAdam Bakula
Adam Bakula
RBRonny Ralf Buechel
Ronny Ralf Buechel

1 September 2013 in International Journal of Cardiology
Verified
Journal Article
Closed access
BSBarbara E. Stähli
Barbara E. Stähli
CGCatherine Gebhard
Catherine Gebhard
PBPatric Biaggi
Patric Biaggi
SKSabine Klaassen
Sabine Klaassen
EBEmanuela Valsangiacomo Buechel
Emanuela Valsangiacomo Buechel
MGMatthias Greutmann
Matthias Greutmann

23 February 2022 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
ARAlexia Rossi
Alexia Rossi
NMNidaa Mikail
Nidaa Mikail
SBSusan Bengs
Susan Bengs
AHAhmed Haider
Ahmed Haider
VTValerie Treyer
Valerie Treyer
CGCatherine Gebhard
Catherine Gebhard
Cardiovascular disease and brain disorders, such as depression and cognitive dysfunction, are highly prevalent conditions and are among the leading causes limiting patient’s quality of life. A growing body of evidence has shown an intimate crosstalk between the heart and the brain, resulting from a complex network of several physiological and neurohumoral circuits. From a pathophysiological perspective, both organs share common risk factors, such as hypertension, diabetes, smoking or dyslipidaemia, and are similarly affected by systemic inflammation, atherosclerosis, and dysfunction of the neuroendocrine system. In addition, there is an increasing awareness that physiological interactions between the two organs play important roles in potentiating disease and that sex- and gender-related differences modify those interactions between the heart and the brain over the entire lifespan. The present review summarizes contemporary evidence of the effect of sex on heart–brain interactions and how these influence pathogenesis, clinical manifestation, and treatment responses of specific heart and brain diseases.